STOCK TITAN

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) will release financial results for Q4 and full year 2023 on March 18, 2024. Conference call with the CEO and CFO to review results on the same day at 8:30 AM ET. Webcast and replay details provided.
Positive
  • None.
Negative
  • None.

CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).

Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

A replay of the conference call will be available until Monday, April 1, 2024, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13743861. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).

Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525


Exagen Inc. will release its financial results for the quarter and year ended December 31, 2023, on March 18, 2024.

John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host the conference call.

Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international) or via webcast on the Exagen investor relations website.

The replay of the conference call will be available until April 1, 2024, at 11:59 PM ET.

A recording of the webcast will be available on the Exagen investor relations website approximately one hour after the call concludes.
Exagen Inc

NASDAQ:XGN

XGN Rankings

XGN Latest News

XGN Stock Data

Dental Laboratories
Manufacturing
Link
Health Services, Medical/Nursing Services, Manufacturing, Dental Laboratories
US
Vista

About XGN

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.